Marjorie Zauderer, M.D., M.S.
Marjorie Zauderer, M.D., M.S., a leading expert and researcher in thoracic malignancies, including mesothelioma serves as Chief of Hematology and Medical Oncology at Westchester Medical Center (WMC). Dr. Zauderer came to NYMC and WMC in 2024 from Memorial Sloan Kettering Cancer Center, where she was Co-Director of the MSK Mesothelioma Program. She has chaired the Board of Directors of the Mesothelioma Applied Research Foundation. With more than 85 peer-reviewed publications, her translational and clinical research, which has been funded by the Department of Defense, the National Cancer Institute, philanthropic sources, and pharmaceutical partners, focuses on the development of novel therapies for the treatment of mesothelioma and lung cancer. She has been at the forefront of developing cellular therapies for mesothelioma and is currently the International Chair of the Steering Committee for the ongoing phase 3 registration trial eVOLVE sponsored by MedImmune.
Education
- Fellowship: Medicine, Weill Cornell Medical Center
- Fellowship: Hematology and Oncology, Memorial Sloan Kettering Cancer Center
- Fellowship: Chief Fellow, Hematology and Oncology, Memorial Sloan Kettering Cancer Center
- Residency: Internal Medicine, Columbia University Medical Center
- Medical: M.D., Columbia University College of Physicians and Surgeons
- Masters: M.S., Molecular Biophysics & Biochemistry, Yale University
- Undergraduate: B.S., Molecular Biophysics & Biochemistry, Yale University
Areas of Expertise
- Lung cancer
- Mesothelioma
Honors and Awards
- 2024 Pioneer Award, Mesothelioma Applied Research Foundation
Research
- Lung cancer
- Mesothelioma
- Novel therapeutics
- Immunotherapies
- Targeted therapies
- Chemotherapy
- Immunotherapy
- Clinical trials
- Surveillance
- Survivorship
Publications
- Agrawal P, Offin M, Lai V, et. al. "Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study." JTO clinical and research reports, 6(1), (2024) 100756. doi: 10.1016/j.jtocrr.2024.100756
- Fanaroff RE, Yang SR, Tan KS, et. al. "Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 38(5), (2025) 100706. doi: 10.1016/j.modpat.2025.100706
- Zauderer MG, Jegede O, Jackman DM, et. al. "Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U." JCO precision oncology, 8(), (2024) e2400327. doi: 10.1200/PO.24.00327
- Altan M, Lopes G, Hiltermann TJN, et. al. "Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research, 31(3), (2025) 529-542. doi: 10.1158/1078-0432.CCR-24-1591
- Offin M, Aguirre N, Yang SR, et. al. "Clinical Characteristics and Outcomes of Patients with Well-Differentiated Papillary Peritoneal Mesothelial Tumors." Annals of surgical oncology, 31(12), (2024) 7973-7977. doi: 10.1245/s10434-024-16004-2
- Mayoral M, Araujo-Filho JAB, Tan KS, et. al. "Are there features that can predict the unresectability of pleural mesothelioma?" European radiology, 35(2), (2025) 806-814. doi: 10.1007/s00330-024-10963-6
- Zauderer MG, Dagogo-Jack I. "Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM trial." The Lancet. Oncology, 25(7), (2024) 825-827. doi: 10.1016/S1470-2045(24)00291-2
Memberships and Affiliations
- Committee, Metastatic Non-Small Cell Lung Cancer, Member
- International Association for the Study of Lung Cancer, Member; Rare Disease Committee Member
- International Mesothelioma Interest Group, Member; 2025 Conference Local Organizing Committee
- Mesothelioma Applied Research Foundation, Board of Directors, Chair
Teaching Responsibilities
- Precepting Hematology & Medical Oncology fellows
- Teaching fellows and residents in clinic and inpatient units
